Medical Strategy
Medical Strategy GmbH is a German boutique asset manager (founded 1992) that runs the MEDICAL BioHealth fund, investing globally in small and mid-cap biotechnology companies. It serves institutional investors, qualified private investors, and financial intermediaries across Germany, Austria, Luxembourg, the Netherlands, Switzerland, and Spain.
- Company typePrivate
- Founded1992
- HeadquartersGräfelfing, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
Medical Strategy firmographics
Firmographics- Name
- Medical Strategy
- Legal name
- Medical Strategy GmbH
- Website
- https://medicalstrategy.de
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medical Strategy GmbH is a German boutique asset manager (founded 1992) that runs the MEDICAL BioHealth fund, investing globally in small and mid-cap biotechnology companies. It serves institutional investors, qualified private investors, and financial intermediaries across Germany, Austria, Luxembourg, the Netherlands, Switzerland, and Spain.
- Ownership category
- akta.pro rank
Medical Strategy industry classification
Industry- Product category
- Biotechnology Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
Keywords
Where Medical Strategy is headquartered
LocationHeadquarters
- HQ city
- Gräfelfing
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Medical Strategy business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund Management Fees: Medical Strategy generates revenue through management fees from their MEDICAL BioHealth investment fund, charging investors for professional portfolio management and biotech investment expertise.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Medical Strategy product offering
Product offeringCore offering
Medical Strategy GmbH manages the MEDICAL BioHealth fund, an open-end public investment fund that invests in equities of small and mid-cap biotechnology companies worldwide. The firm uses scientific fundamental analysis to evaluate companies with innovative drug development pipelines and actively engages in dialogue with portfolio company management to support investment outcomes.
Product overview
Medical Strategy is an investment management firm that operates as a single-product company, offering the MEDICAL BioHealth open-end fund. This fund provides exposure to the global biotechnology sector by investing primarily in small and mid-cap biotech companies that are developing innovative therapies and drugs. The company uses a scientifically fundamental analysis approach to identify investment opportunities in the health and biotechnology growth market.
Differentiator
Problem solved
Functional benefit
Products and services
- MEDICAL BioHealth
Companies that use Medical Strategy
Customer profileSegments3 records
Ideal customer profiles3 records
Medical Strategy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Medical Strategy partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights4 records
Medical Strategy competitors and assessment
Company assessmentBroad incumbents
- BlackRock: Largest global asset manager offering the World Healthscience Fund and other healthcare strategies; competes with Medical Strategy for the institutional biotech/healthcare allocation across European LPs.
- DWS Group: Major German asset manager (formerly Deutsche AM) with healthcare and innovation-focused funds; a key DACH competitor for biotech fund shelf-space with retail banks and intermediaries.
- Franklin Templeton: Global asset manager with dedicated biotech and healthcare funds (e.g., Franklin Biotechnology Discovery Fund); competes for institutional biotech allocations at larger scale.
- Pictet Asset Management: Swiss incumbent offering Pictet Biotech and broader thematic health strategies; broader portfolio but directly overlaps in European biotech fund distribution.
- Allianz Global Investors: German-headquartered global asset manager with healthcare/biotech strategies; directly competes with Medical Strategy in DACH institutional and intermediary channels.
Direct peers
- Polar Capital: UK-based specialist active manager running a Healthcare Biotechnology Opportunities Fund; targets European institutional investors with a similar small/mid-cap biotech thesis.
- BB Biotech AG: Swiss-listed investment company focused on small/mid-cap biotech with a scientific fundamental approach; the closest single-strategy competitor to MEDICAL BioHealth in the listed European biotech-investment space.
- Bellevue Asset Management: Swiss specialist asset manager best known for BB Biotech and dedicated healthcare/biotech strategies; competes head-to-head with Medical Strategy for the same European institutional and intermediary biotech mandates.
Emerging players
- Lupus alpha: Frankfurt-based specialist active manager known for niche equity strategies; comparable as a smaller German specialist competing for institutional DACH mandates, though not biotech-only.
Regional players
- Edmond de Rothschild Asset Management: European boutique with healthcare/biotech strategies distributed primarily in France, Switzerland, and continental Europe; comparable specialist active manager competing for European healthcare mandates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Medical Strategy social profiles
Digital presenceMedical Strategy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medical Strategy leadership team
Management profileNumber of profiles
Profiles2 records
Medical Strategy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medical Strategy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medical Strategy
What does Medical Strategy do?
Medical Strategy GmbH manages the MEDICAL BioHealth fund, an open-end public investment fund that invests in equities of small and mid-cap biotechnology companies worldwide. The firm uses scientific fundamental analysis to evaluate companies with innovative drug development pipelines and actively engages in dialogue with portfolio company management to support investment outcomes.
Is Medical Strategy a public or private company?
Medical Strategy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medical Strategy founded?
Medical Strategy was founded in 1992. It employs 11 to 50 people.
Where is Medical Strategy based?
Medical Strategy is headquartered in Gräfelfing, Germany, in the Europe region.
How does Medical Strategy make money?
One revenue line is on record: fund Management Fees.
Who are Medical Strategy's main competitors?
Broad incumbents on record are BlackRock, DWS Group, Franklin Templeton, Pictet Asset Management and Allianz Global Investors. Direct peers are Polar Capital, BB Biotech AG and Bellevue Asset Management. Lupus alpha is listed as an emerging player. Edmond de Rothschild Asset Management is listed as a regional player.
Does Medical Strategy have an API?
No public API is recorded for Medical Strategy.
What industry is Medical Strategy in?
Medical Strategy's product category is Biotechnology Investment Management. Its primary akta.pro industry code is FSANAJAI, Healthcare Access & Life Sciences Impact Funds. Its NAICS code is 523940 and its SIC code is 6282.